Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension

Journal of Controlled Release

Volumn 167, Issue 2, 2013, Pages 189-199

  Gupta, Vivek ^a,e   Gupta, Nilesh ^a   Shaik, Imam H ^a   Mehvar, Reza ^a   McMurtry, Ivan F ^b   Oka, Masahiko ^b   Nozik Grayck, Eva ^c   Komatsu, Masanobu ^d   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c Nutrition Obesity Research Center at the University of Colorado   (United States)

^d BURNHAM INSTITUTE   (United States)

^e Santa Barbara   (United States)

Author keywords

Ammonium sulfate; Fasudil; Liposomes; Pulmonary arterial pressure; Pulmonary delivery

Indexed keywords

AMMONIUM SULFATE; ARTERIAL PRESSURES; ELECTROCHEMICAL GRADIENTS; FASUDIL; INTRATRACHEAL INSTILLATION; PULMONARY ARTERIAL HYPERTENSION; PULMONARY ARTERIAL HYPERTENSION (PAH); PULMONARY DELIVERY;

LIPOSOMES; OPTIMIZATION;

ENZYME INHIBITION;

AMMONIUM SULFATE; FASUDIL; LIPOSOME; MONOCROTALINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG FORMULATION; DRUG RELEASE; ELECTROCHEMICAL ANALYSIS; ENCAPSULATION; HYDRATION; HYPOTHESIS; MALE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; VASODILATATION;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AEROSOLS; ALKALINE PHOSPHATASE; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; CELL SURVIVAL; CHOLESTEROL; DRUG STABILITY; HYPERTENSION, PULMONARY; L-LACTATE DEHYDROGENASE; LIPOSOMES; MACROPHAGES, ALVEOLAR; MALE; MYOCYTES, SMOOTH MUSCLE; PROTEIN KINASE INHIBITORS; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; VASODILATION; VASODILATOR AGENTS;

EID: 84874397036     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.01.011     Document Type: Article

References (51)

1. P.A. Corris Alternatives to lung transplantation: treatment of pulmonary arterial hypertension Clin. Chest Med. 32 2011 399 410
2. J.L. Vachiery Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy Adv. Ther. 28 2011 251 269
3. L. Chen, K. Nakano, S. Kimura, T. Matoba, E. Iwata, M. Miyagawa, H. Tsujimoto, K. Nagaoka, J. Kishimoto, K. Sunagawa, and K. Egashira Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension Hypertension 57 2011 343 350
4. S. Kimura, K. Egashira, L. Chen, K. Nakano, E. Iwata, M. Miyagawa, H. Tsujimoto, K. Hara, R. Morishita, K. Sueishi, R. Tominaga, and K. Sunagawa Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension Hypertension 53 2009 877 883
5. V. Gupta, A. Rawat, and F. Ahsan Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension J. Pharm. Sci. 99 2010 1774 1789
6. M.M. Bailey, and C.J. Berkland Nanoparticle formulations in pulmonary drug delivery Med. Res. Rev. 29 2009 196 212
7. K.M. Taylor, and J.M. Newton Liposomes for controlled delivery of drugs to the lung Thorax 47 1992 257 259
8. R. Bhavane, E. Karathanasis, and A.V. Annapragada Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery J. Control. Release 93 2003 15 28
9. A.S. Ulrich Biophysical aspects of using liposomes as delivery vehicles Biosci. Rep. 22 2002 129 150
10. G. Lopez-Berestein Liposomes as carriers of antimicrobial agents Antimicrob. Agents Chemother. 31 1987 675 678
11. F. Hajos, B. Stark, S. Hensler, R. Prassl, and W. Mosgoeller Inhalable liposomal formulation for vasoactive intestinal peptide Int. J. Pharm. 357 2008 286 294
12. E. Kleemann, T. Schmehl, T. Gessler, U. Bakowsky, T. Kissel, and W. Seeger Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability Pharm. Res. 24 2007 277 287
13. B. Stark, P. Debbage, F. Andreae, W. Mosgoeller, and R. Prassl Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery Biochim. Biophys. Acta 1768 2007 705 714
14. M. Oka, K.A. Fagan, P.L. Jones, and I.F. McMurtry Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension Br. J. Pharmacol. 155 2008 444 454
15. M. Shibuya, S. Hirai, M. Seto, S. Satoh, and E. Ohtomo Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial J. Neurol. Sci. 238 2005 31 39
16. J.A. Zhang, G. Anyarambhatla, L. Ma, S. Ugwu, T. Xuan, T. Sardone, and I. Ahmad Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation Eur. J. Pharm. Biopharm. 59 2005 177 187
17. B. Patel, V. Gupta, and F. Ahsan PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin J. Control. Release 162 2012 310 320
18. S. Bai, and F. Ahsan Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism J. Pharm. Sci. 99 2010 4554 4564
19. T. Ishida, Y. Takanashi, H. Doi, I. Yamamoto, and H. Kiwada Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes Int. J. Pharm. 232 2002 59 67
20. V. Gupta, M. Davis, L.J. Hope-Weeks, and F. Ahsan PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-beta-cyclodextrin (PGE1-HPbetaCD) complex for the treatment of pulmonary arterial hypertension (PAH) Pharm. Res. 28 2011 1733 1749
21. J.T. Crossno Jr., C.V. Garat, J.E. Reusch, K.G. Morris, E.C. Dempsey, I.F. McMurtry, K.R. Stenmark, and D.J. Klemm Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling Am. J. Physiol. Lung Cell. Mol. Physiol. 292 2007 L885 L897
22. S.B. Kulkarni, G.V. Betageri, and M. Singh Factors affecting microencapsulation of drugs in liposomes J. Microencapsul. 12 1995 229 246
23. F. Lewrick, and R. Suss Remote loading of anthracyclines into liposomes Methods Mol. Biol. 605 2010 139 145
24. L.D. Mayer, M.B. Bally, and P.R. Cullis Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient Biochim. Biophys. Acta 857 1986 123 126
25. J.C. Ong, F. Sun, and E. Chan Development of stealth liposome coencapsulating doxorubicin and fluoxetine J. Liposome Res. 21 2011 261 271
26. S. Tu, T. McGinnis, L. Krugner-Higby, and T.D. Heath A mathematical relationship for hydromorphone loading into liposomes with trans-membrane ammonium sulfate gradients J. Pharm. Sci. 99 2010 2672 2680
27. G. Haran, R. Cohen, L.K. Bar, and Y. Barenholz Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases Biochim. Biophys. Acta 1151 1993 201 215
28. P.S. Uster, T.M. Allen, B.E. Daniel, C.J. Mendez, M.S. Newman, and G.Z. Zhu Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time FEBS Lett. 386 1996 243 246
29. N. Dos Santos, K.A. Cox, C.A. McKenzie, F. van Baarda, R.C. Gallagher, G. Karlsson, K. Edwards, L.D. Mayer, C. Allen, and M.B. Bally pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol Biochim. Biophys. Acta 1661 2004 47 60
30. A. Ertel, A.G. Marangoni, J. Marsh, F.R. Hallett, and J.M. Wood Mechanical properties of vesicles. I. Coordinated analysis of osmotic swelling and lysis Biophys. J. 64 1993 426 434
31. M. Bunuales, N. Duzgunes, S. Zalba, M.J. Garrido, and C.T. de Ilarduya Efficient gene delivery by EGF-lipoplexes in vitro and in vivo Nanomedicine 6 2011 89 98
32. J.A. Zasadzinski Transmission electron microscopy observations of sonication-induced changes in liposome structure Biophys. J. 49 1986 1119 1130
33. T. Ishida, Y. Takanashi, and H. Kiwada Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil Biol. Pharm. Bull. 29 2006 397 402
34. D.L.R.L. Biltonen The use of differential scanning calorimetry as a tool to characterize liposome preparations Chem. Phys. Lipids 64 1993 129 142
35. L.H. Lindner, and M. Hossann Factors affecting drug release from liposomes Curr. Opin. Drug Discov. Devel. 13 2010 111 123
36. S. Chono, T. Tanino, T. Seki, and K. Morimoto Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification J. Pharm. Pharmacol. 59 2007 75 80
37. A. Masumoto, M. Mohri, H. Shimokawa, L. Urakami, M. Usui, and A. Takeshita Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina Circulation 105 2002 1545 1547
38. H. Shimokawa, M. Seto, N. Katsumata, M. Amano, T. Kozai, T. Yamawaki, K. Kuwata, T. Kandabashi, K. Egashira, I. Ikegaki, T. Asano, K. Kaibuchi, and A. Takeshita Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm Cardiovasc. Res. 43 1999 1029 1039
39. J.A. Champion, A. Walker, and S. Mitragotri Role of particle size in phagocytosis of polymeric microspheres Pharm. Res. 25 2008 1815 1821
40. K. Makino, N. Yamamoto, K. Higuchi, N. Harada, H. Ohshima, and H. Terada Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres Colloids Surf. B Biointerfaces 27 2003 33 39
41. J.E. Duncan, G.M. Hatch, and J. Belik Susceptibility of exogenous surfactant to phospholipase A2 degradation Can. J. Physiol. Pharmacol. 74 1996 957 963
42. L. Dizon-Co, M. Ikegami, T. Ueda, A.H. Jobe, W.H. Lin, J.G. Turcotte, R.H. Notter, and E.D. Rider In vivo function of surfactants containing phosphatidylcholine analogs Am. J. Respir. Crit. Care Med. 150 1994 918 923
43. L. Todd, M. Mullen, P.M. Olley, and M. Rabinovitch Pulmonary toxicity of monocrotaline differs at critical periods of lung development Pediatr. Res. 19 1985 731 737
44. R.J. van Suylen, J.F. Smits, and M.J. Daemen Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension Am. J. Respir. Crit. Care Med. 157 1998 1423 1428
45. Y. Fukumoto, T. Matoba, A. Ito, H. Tanaka, T. Kishi, S. Hayashidani, K. Abe, A. Takeshita, and H. Shimokawa Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension Heart 91 2005 391 392
46. T. Nagaoka, K.A. Fagan, S.A. Gebb, K.G. Morris, T. Suzuki, H. Shimokawa, I.F. McMurtry, and M. Oka Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension Am. J. Respir. Crit. Care Med. 171 2005 494 499
47. B.H. Jiang, S. Tawara, K. Abe, A. Takaki, Y. Fukumoto, and H. Shimokawa Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats J. Cardiovasc. Pharmacol. 49 2007 85 89
48. I. Mahmood Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development Adv. Drug Deliv. Rev. 59 2007 1177 1192
49. Guidance for Industry: Estimating the Maximum safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005 Center for Drug Evaluation and Research, Food and Drug Administration Rockville, MD 1 27
50. H. Fujita, Y. Fukumoto, K. Saji, K. Sugimura, J. Demachi, J. Nawata, and H. Shimokawa Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension Heart Vessels 25 2010 144 149
51. V. Gupta, and F. Ahsan Inhalational therapy for pulmonary arterial hypertension: current status and future prospects Crit. Rev. Ther. Drug Carrier Syst. 27 2010 313 370